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and 7,668 euros respectively. For the replacement
approach the costs for severe, moderate and mild patients
were 25,333, 16,631, and 9,932 euros respectively. 
Informal support and costs, in terms of ADL, IADL,
Social/recreation and Behaviour increased with Alzheimer
severity. CONCLUSIONS: This study gives some new
perspectives on informal care giving for persons with
Alzheimer. Informal care for Alzheimer represent a sig-
niﬁcant hidden cost to Spanish society. This aspect of
caring must be addressed by the development of well-
targeted respite and relief support programmes. Because
the Spanish community is rapidly aging, this informal
care burden may increase signiﬁcantly in the future.
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OBJECTIVES: Placebo-controlled clinical trials have
demonstrated the efﬁcacy of memantine versus placebo in
moderately severe and severe Alzheimer’s disease. A mod-
elling approach has been adopted to estimate costs and
outcomes of memantine treatment in clinical practice in
Spain. METHODS: A Markov model simulated moder-
ately severe and severe patients’ progression through
levels of combinations of severity, autonomy, and setting
over ﬁve years. Model inputs include clinical trial results
and measurement of patient and caregiver resource utili-
sation from a societal perspective using literature and
expert data. The main outcome measures were time spent
in autonomy (patient’s ability to accomplish activities
using the ADCS-ADL scale) and time to institutionalisa-
tion. This cost-effectiveness study compared the meman-
tine treatment strategy to that of no pharmacotherapy
and to donepezil for patients with moderately severe AD
followed by no pharmacotherapy when patients reach the
severe AD level. RESULTS: The time spent in autonomy
for patients treated with memantine is 14% longer in
duration than for patients treated with donepezil and
25% longer than for patients without pharmacotherapy.
The delay time to institutionalisation was 8% longer with
memantine compared with donepezil and 12% longer
with memantine compared with no treatment. Over a 5-
year period, patients treated with memantine showed a
decrease of €268 and €511 in total Health care costs,
compared with donepezil and no treatment, respectively.
Robustness of the results was validated by a comprehen-
sive sensitivity analysis. CONCLUSION: Memantine is
more effective in increasing time spent in autonomy and
in reducing Health care costs compared with donepezil or
no pharmacotherapy.
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OBJECTIVES: To assess the impact of DBS of the STN
on HRQOL and on Health care resource use in French
advanced parkinsonian patients and to estimate the cost
of the procedure. METHODS: SPARK is an observational
prospective multicentre study using a before-after
methodology carried out between November 1998 and
March 2002 in a cohort of 88 patients with severe Parkin-
son’s disease (PD). Quality of life was assessed before
surgery and at 12-month follow-up using a speciﬁc instru-
ment, the PDQL 37 (Parkinson’s Disease Quality of Life)
that has a 3-month recall period. The resource use data
were monthly collected from individual questionnaires.
Two periods of observation were considered: the ﬁrst 6
months prior surgery and from the 6th to the 12th month
after surgery. The cost of the procedure (surgery, mater-
ial and checkups over 1 year) was assessed from data 
collected in the 4 centres. The economic analysis was 
performed from a Health Insurance perspective.
RESULTS: About 66% of patients were men. The mean
age of patients was 57.3 ± 7.7 years with a mean dura-
tion of PD of 13.9 ± 5.0 years. At 12-month follow-up
after surgery, the quality of life was signiﬁcantly improved
(+28%, p < 0.0001). All the PDQL subscores were con-
cerned by this improvement, especially the social dimen-
sion (+43.5%, p < 0.0001). The average 6-monthly cost
decreased from €10,087 ± 4,887 prior surgery to €1,673
± 2,111 after surgery (€-8,415 ± 4,438, p < 0.0001).
Taking into account costs related to adjustments of the
parameters of the stimulator, the difference was reduced
but remained signiﬁcant: €-7,275 ± 5,128 (p < 0.0001).
The most important savings came from a dramatically
decrease in medication use. CONCLUSIONS: Our ﬁnd-
ings showed a signiﬁcant impact of DBS on HRQOL and
on medical resource use in patients with PD.
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OBJECTIVES: The purpose was to develop an early 
decision-making model for Parkinson disease (PD) and 
to assess the cost-effectiveness of neural transplanta-
tion (NT) compared to standard treatment in PD.
